Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Inc. shares headed into Monday’s session under fresh scrutiny after a late-Friday ownership filing added another data point to a stock already being driven less by drug-development news than by restructuring, Nasdaq compliance and cash runway.

18 May 2026

NASDAQ:QNCX · Stock Market

Upcoming Stock Splits This Week: Nasdaq Reverse Splits Pile Up as Booking, Powell and Pashupati Stand Apart

Nasdaq names set for reverse splits Monday include NextPlat, MultiSensor AI, Cenntro, and Quince Therapeutics. The split roster for April 13-17 has flipped from last week’s action, which featured forward splits at Booking Holdings and Powell Industries.

13 April 2026

Nasdaq·NASDAQ:BKNG·NASDAQ:CNTRO·NASDAQ:MSAI·NASDAQ:NXPL·NASDAQ:POWL·NASDAQ:QNCX·Stock Market

Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive

Quince Therapeutics jumped roughly 48% to 78 cents in premarket action Wednesday, building on a steep rally that followed news the company brought in an adviser to weigh strategic alternatives.

11 February 2026

NASDAQ:QNCX·Stock Market

Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move

Quince Therapeutics, Inc. dropped 6.6% to about $0.13 in premarket trading Tuesday. The biotech’s shares have been volatile lately, reacting to a string of company updates and regulatory decisions.

10 February 2026

NASDAQ:QNCX·Stock Market